Compare Stocks → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AYLANASDAQ:FENCNASDAQ:GMDANASDAQ:GNFTNASDAQ:IDRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.48$0.36▼$7.31$7.46M1.9876,300 shs137,700 shsFENCFennec Pharmaceuticals$9.07-1.8%$10.05$6.30▼$11.92$250.40M0.38115,039 shs182,107 shsGMDAGamida Cell$0.02$0.23$0.03▼$2.51$2.33M0.939.20 million shs585,431 shsGNFTGenfit$3.45$3.59$2.89▼$4.75$171.66M1.0814,909 shs3,539 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%FENCFennec Pharmaceuticals-1.84%-6.49%-17.55%-12.96%+14.09%GMDAGamida Cell-8.62%-11.18%-95.53%-96.30%-99.04%GNFTGenfit+0.44%-0.43%-5.36%-11.21%-7.89%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Will this $2 AI stock double overnight? (Ad)It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.4106 of 5 stars3.50.00.00.02.32.51.9GMDAGamida Cell0.5988 of 5 stars3.42.00.00.00.00.80.0GNFTGenfit0.81 of 5 stars3.53.00.00.00.60.00.0IDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala PharmaceuticalsN/AN/AN/AN/AFENCFennec Pharmaceuticals3.00Buy$17.3391.11% UpsideGMDAGamida Cell2.75Moderate Buy$4.7531,356.95% UpsideGNFTGenfit3.00Buy$11.00219.30% UpsideIDRAIdera PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest FENC, GMDA, GNFT, IDRA, and AYLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.001/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M0.00N/AN/A$2.45 per share0.00FENCFennec Pharmaceuticals$21.25M11.57N/AN/A($0.43) per share-21.09GMDAGamida Cell$1.78M1.30N/AN/A($0.02) per share-0.76GNFTGenfit$41.31M4.16N/AN/A$1.48 per share2.33IDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/AFENCFennec Pharmaceuticals-$16.05M-$0.61N/A12.96N/A-75.50%N/A-73.64%5/9/2024 (Estimated)GMDAGamida Cell-$63M-$0.63N/A∞N/AN/AN/A-57.59%5/20/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)IDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/ALatest FENC, GMDA, GNFT, IDRA, and AYLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28FENCFennec PharmaceuticalsN/A3.563.27GMDAGamida Cell213.142.162.09GNFTGenfit0.922.942.94IDRAIdera PharmaceuticalsN/A1.561.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%FENCFennec Pharmaceuticals55.51%GMDAGamida Cell50.34%GNFTGenfit2.24%IDRAIdera Pharmaceuticals12.18%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%FENCFennec Pharmaceuticals11.25%GMDAGamida Cell3.40%GNFTGenfit4.20%IDRAIdera Pharmaceuticals5.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableFENC, GMDA, GNFT, IDRA, and AYLA HeadlinesSourceHeadlineEkso Bionics (NASDAQ: EKSO)fool.com - April 11 at 12:41 PMKiniksa Pharmaceuticalsforbes.com - November 15 at 3:23 PMIdra Pin Codeindiatvnews.com - August 24 at 7:09 PMNabriva Therapeutics AG (NBRVF)investing.com - August 9 at 2:08 AMTesla's Switch to Giga Press Die Castings for Model 3 Eliminates 370 Partsdesignnews.com - May 21 at 8:54 AMMarginalianpr.org - April 26 at 9:17 PMA mysterious rift propels the story in ‘Take What You Need’washingtonpost.com - March 17 at 5:57 PMIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlookfinanznachrichten.de - January 18 at 7:34 AMIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic ...bakersfield.com - January 17 at 11:33 AMIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlookfinance.yahoo.com - January 17 at 11:33 AMWhy Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionmsn.com - January 10 at 7:29 PMIdera (IDRA) Stock Soars on GlaxoSmithKline Partnershipthestreet.com - January 4 at 12:55 PMIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - November 18 at 3:52 PMIdera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 14 at 5:55 PMIdera Pharma Acquires Rare Disease Player, Names New CEOfinance.yahoo.com - September 29 at 3:46 PMIdera Pharma Shares Rise Nearly 18% After Aceragen Acquisitionmarketwatch.com - September 28 at 6:34 PMIdera Pharmaceuticals Acquires Aceragenfinance.yahoo.com - September 28 at 6:34 PMIdera Pharmaceuticals Stock (NASDAQ:IDRA), Dividendsbenzinga.com - September 27 at 10:32 PMIdera Pharmaceuticals Reports Second Quarter 2022 Financial Resultsfinance.yahoo.com - August 9 at 9:26 PMIdera Pharmaceuticals Inc. [IDRA] Is Currently 16.02 above its 200 Period Moving Avg: What Does This Mean?dbtnews.com - May 18 at 5:18 PMIdera halts melanoma trial for cancer candidate after early positive resultsseekingalpha.com - May 17 at 6:10 PMWhy Are Idera Pharmaceuticals Shares Soaring Todayfinance.yahoo.com - May 17 at 6:10 PMIdera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMCfinance.yahoo.com - May 17 at 8:18 AMIdera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 5 at 6:17 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Idera PharmaceuticalsNASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.